HELP (Helus Pharma) ROC (Joel Greenblatt) %: -1,928.05% (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

HELP Helus Pharma Inc HELP
33 GF Score
Price $7.25
! 2 Warning Signs
View Full Analysis

What is Helus Pharma ROC (Joel Greenblatt) %?

Helus Pharma HELP +3.13% 33 ROC (Joel Greenblatt) % is -1,928.05% as of Mar. 2026. GuruFocus rates HELP with a GF Score™ of 33/100. The stock has 2 warning signs investors should review. Among 1,324 Biotechnology companies, Helus Pharma ranks worse than 70.32% on this metric.

Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits). He defines ROC (Joel Greenblatt) % as EBIT divided by the total of Property, Plant and Equipment and net working capital. Helus Pharma's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2026 was -1,928.05%.

The historical rank and industry rank for Helus Pharma's ROC (Joel Greenblatt) % or its related term are showing as below:

HELP' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -12306.84   Med: -5707.11   Max: -1296.12
Current: -1296.12

During the past 7 years, Helus Pharma's highest ROC (Joel Greenblatt) % was -1296.12%. The lowest was -12306.84%. And the median was -5707.11%.

HELP's ROC (Joel Greenblatt) % is ranked worse than
70.32% of 1324 companies
in the Biotechnology industry
Industry Median: -297.95 vs HELP: -1296.12

Helus Pharma's 5-Year average Growth Rate of ROC (Joel Greenblatt) % was 23.90% per year.


Helus Pharma  (NAS:HELP) ROC (Joel Greenblatt) % Explanation

The way Joel Greenblatt defines Return on Capital is a more accurate measure of how efficiently the company generates returns onthe capital actually invested in the business. EBIT is used instead of net income because the tax and interest payment may be affected by factors other than the core business operation. Intangible assets are not included in the calculation because they don't need to be replaced.

Joel Greenblatt uses his definition of Return on Capital and Earnings Yield (Joel Greenblatt) % to rank companies.


Helus Pharma ROC (Joel Greenblatt) % Related Terms


Helus Pharma ROC (Joel Greenblatt) % Historical Data

* Premium members only.

The historical data trend for Helus Pharma's ROC (Joel Greenblatt) % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Helus Pharma ROC (Joel Greenblatt) % Chart

Helus Pharma Annual Data
Trend Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
ROC (Joel Greenblatt) %
Get a 7-Day Free Trial -12,262.11 -5,508.03 -8,364.87 -2,891.49 -1,925.55

Helus Pharma Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
ROC (Joel Greenblatt) % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -952.81 -1,144.30 -823.22 -1,122.58 -1,928.05

HELP vs VRTX, REGN, ALNY: ROC (Joel Greenblatt) % Comparison

For the Biotechnology subindustry, Helus Pharma's ROC (Joel Greenblatt) %, along with its competitors' market caps and ROC (Joel Greenblatt) % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Helus Pharma ROC (Joel Greenblatt) % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Helus Pharma's ROC (Joel Greenblatt) % distribution charts can be found below:

* The bar in red indicates where Helus Pharma's ROC (Joel Greenblatt) % falls into.


HELP
33GF Score
Helus Pharma Inc HELP
ROC (Joel Greenblatt) % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Helus Pharma ROC (Joel Greenblatt) % Calculation

Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits) . He defines Return on Capital as follows:

ROC (Joel Greenblatt) %=EBIT/Average of (Net fixed Assets + Net Working Capital)

EBIT stands for Earnings Before Interest and Taxes.

Fixed Assets are also known as non-current assets. They include the Property, Plant and Equipment that the firm needs in its operation.

GuruFocus calculates net working capital as: (Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Deferred Revenue + Other Current Liabilities). We're trying to account for OPERATING assets and liabilities (part of daily business) when calculating working capital. Cash and marketable securities are considered NON-OPERATING assets and are not included in calculation. We will also back out all interest bearing debt, short term debt and the portion of long term debt that is due in the current period from the current liabilities. This debt will be considered when computing cost of capital and it would be inappropriate to count it twice.

Working Capital(Q: Dec. 2025 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(4.766 + 0 + 23.002) - (16.178 + 0 + 0)
=11.59

Working Capital(Q: Mar. 2026 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(5.028 + 0 + 22.236) - (19.377 + 0 + 0)
=7.887

When net working capital is negative, 0 is used.

So ROC (Joel Greenblatt) % of Helus Pharma for the quarter that ended in Mar. 2026 can be restated as:

ROC (Joel Greenblatt) %(Q: Mar. 2026 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Dec. 2025  Q: Mar. 2026
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=-191.436/( ( (0.186 + max(11.59, 0)) + (0.195 + max(7.887, 0)) )/ 2 )
=-191.436/( ( 11.776 + 8.082 )/ 2 )
=-191.436/9.929
=-1,928.05 %

Note: The EBIT data used here is four times the quarterly (Mar. 2026) EBIT data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a ROC (Joel Greenblatt) % of -1,928.05% mean?
Helus Pharma (HELP) has a ROC (Joel Greenblatt) % of -1,928.05% as of Mar. 2026. Joel Greenblatt's return on capital is the ratio of EBIT to average fixed assets and net working capital. View historical data on Helus Pharma and its competitors. According to the industry distribution chart, Helus Pharma ranks #931 out of 1324 companies in the Biotechnology industry, placing it in the top 70.3%.
Is Helus Pharma's ROC (Joel Greenblatt) % too high?
Helus Pharma's current ROC (Joel Greenblatt) % is -1,928.05%. Based on the distribution chart, Helus Pharma ranks #931 out of 1324 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Helus Pharma has a GF Score™ of 33/100, reflecting its overall financial health beyond just this single metric.
How does Helus Pharma's ROC (Joel Greenblatt) % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Helus Pharma ranks #931 out of 1324 companies for ROC (Joel Greenblatt) %. This places Helus Pharma in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROC (Joel Greenblatt) % for a Biotechnology company?
A good ROC (Joel Greenblatt) % depends on the Biotechnology industry context. However, ROC (Joel Greenblatt) % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROC (Joel Greenblatt) % mean?
A high ROC (Joel Greenblatt) % can signal that a stock is expensive relative to its fundamentals. Joel Greenblatt's return on capital is the ratio of EBIT to average fixed assets and net working capital. View historical data on Helus Pharma and its competitors. Helus Pharma's current ROC (Joel Greenblatt) % is -1,928.05%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Helus Pharma stock overvalued right now?
Helus Pharma (HELP) has a current ROC (Joel Greenblatt) % of -1,928.05%. The current ROC (Joel Greenblatt) % is -1,928.05%. Helus Pharma's overall GF Score™ is 33/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROC (Joel Greenblatt) % calculated?
ROC (Joel Greenblatt) % is calculated from a company's financial statements. For Helus Pharma (HELP), the current ROC (Joel Greenblatt) % is -1,928.05% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Helus Pharma Business Description

Other Exchanges R7E:GermanyHELP:Canada
Address 100 King Street West, Suite 5600, Toronto, ON, CAN, M5X 1C9
Helus Pharma Inc, the commercial operating name of Cybin Inc, is a clinical-stage pharmaceutical company focused on developing proprietary neuroactive compounds, referred to as NSAs, which are synthetic molecules designed to target serotonin pathways. The company's programs are aimed at treating mental health conditions such as depression and anxiety. Its pipeline includes HLP003, which is in clinical development for the adjunctive treatment of depressive disorder, and HLP004, which is in clinical development for generalized anxiety disorder. The company also conducts research on additional investigational compounds.
33GF Score

Get the complete analysis for HELP

ROC (Joel Greenblatt) % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$7.25
Price